Quanta Fluid News

Quanta Appoints World Leading Nephrologist to Medical Advisory Board

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces it has appointed Dr Sandip Mitra to its Medical Advisory Board.

Sandip is a practising Senior Consultant Nephrologist at Manchester Royal Infirmary where he leads one of the largest home haemodialysis programmes in Europe. He is a Principal Investigator on multicentre trials and is a recognised international advisor to global industry leaders in dialysis. Over the past 12 years he has held a number of research and clinical positions, including Renal Speciality Research Lead for the Clinical Research Network NIHR; Chair of Clinical Research Study Group for the UK Kidney Research Consortium NIHR; Renal Innovation Lead at MAHSC & Manchester Integrating Medicine & Innovative Technology (MIMIT); Clinical Chair, Renal Technology at NIHR Devices for Dignity; Senior Lecturer at the University of Manchester; and Clinical and Governance Lead for the Hospital, Home and Minimal Care HD.

Sandip qualified as a doctor in India and has since received speciality training in nephrology in Stevenage, Oxford and Manchester. Sandip has written extensive research on uraemia and dialytic therapies at University College London, Royal Free Medical School. He was previously Senior Research Fellow UCL, Royal Free Hospitals and Lister Hospital in Hertfordshire. He has won multiple awards for his work, research and innovation, including the Health Service Top Innovator Award in 2013, National Award Winner of the NHS Innovation Challenge and NICE excellence Award in 2011 as well as the British Journal of Renal Medicine Awards in 2010.

John E. Milad, Chief Executive Officer of Quanta, said “We are delighted that Sandip has chosen to join our Medical Advisory Board. He is a world-leading nephrologist and understands that innovation can be a powerful enabler for improving patient outcomes and experiences in dialysis, whilst achieving better value for money. Over the course of the last decade, Dr Mitra has been a tireless champion of home dialysis and I look forward to working with him as we expand the use of SC+ within the NHS.”

Recent Articles

Endotronix News

FDA Approval for Endotronix Pivotal Trial

Dublin, Ireland and LISLE, IL, USA – AUGUST 1, 2019 – Seroba’s portfolio company, Endotronix, Inc., a digital health and […]

Read More
Quanta News

Quanta Raises $48 million in Series C Funding Round

Alcester, Warwickshire, UK, 29 July 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical […]

Read More
Endotronix News

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial

LISLE, IL – JULY 15, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the […]

Read More
Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top